Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-3112 with CRT in locally advanced cervical cancer
NCT02501278Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MEDI0457 in Cervical Cancer (CC) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Occurrence of Adverse Events at 6 months and Progression-Free Survival at 18 months. Planned start May 2016; status: withdrawn.
02
Drugs
MEDI0457
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02501278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501278.